



Antimicrobial Resistance of Mycobacterium Tuberculosis: Old and New Drugs

Guest Editor:

Dr. Danila V. Zimenkov

Center for Precision Genome
Editing and Genetic Technologies
for Biomedicine, Engelhardt
Institute of Molecular Biology,
Russian Academy of Sciences,
Moscow, Russia

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

Dear Colleagues,

The limited number of antituberculosis drugs and the quick rise of drug resistance are serious public health threats, demanding the development of novel drugs and regimens for successful treatment. To reach the aim of personalized treatment that accounts for resistance, many molecular assays are under development complementing classical phenotypic methods.

In addition to the identification of resistance-associated mutations and epidemiology surveillance, studies of microevolution have resulted in the identification of fitness compensatory mechanisms and the epistatic impact of genetic background on resistance development. The list of resistance determinants is expanding, and further analysis of resistant clinical strains is urgently needed to improve the reliability of molecular methods and our understanding of evolution.

This Special Issue seeks manuscript submissions that expand our understanding of drug-resistant tuberculosis, mechanisms, surveillance, and novel approaches to therapy.

Keywords : tuberculosis; drug resistance; resistance determinants; genome organization; epidemiology and surveillance





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi